1. Home
  2. DXC vs IOVA Comparison

DXC vs IOVA Comparison

Compare DXC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DXC Technology Company

DXC

DXC Technology Company

SELL

Current Price

$12.51

Market Cap

1.7B

Sector

Technology

ML Signal

SELL

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

SELL

Current Price

$14.44

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DXC
IOVA
Founded
1959
2007
Country
United States
United States
Employees
115000
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2016
2008

Fundamental Metrics

Financial Performance
Metric
DXC
IOVA
Price
$12.51
$14.44
Analyst Decision
Hold
Buy
Analyst Count
8
10
Target Price
$11.21
★ $14.40
AVG Volume (30 Days)
3.4M
★ 14.0M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 14.84
EPS
★ 0.73
N/A
Revenue
★ $12,644,000,000.00
N/A
Revenue This Year
N/A
$56.63
Revenue Next Year
N/A
$42.41
P/E Ratio
$17.18
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.90
$1.76
52 Week High
$15.68
$15.06

Technical Indicators

Market Signals
Indicator
DXC
IOVA
Relative Strength Index (RSI) 65.02 72.11
Support Level $11.26 $3.57
Resistance Level $13.38 $15.06
Average True Range (ATR) 0.46 0.80
MACD 0.16 0.05
Stochastic Oscillator 91.05 88.36

Price Performance

Historical Comparison
DXC
IOVA

About DXC DXC Technology Company

DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: